The APCCC in Basel, Switzerland: Day 1

So in this series of reports on what happened at the 3rd Advanced Prostate Cancer Consensus Conference (APCCC) in Basel, Switzerland, we will not be trying to get into detail about exactly what data got presented each day. … READ MORE …

Update on STAMPEDE data on abiraterone + ADT in M0 patients with HSPC

Three months ago, James et al. presented the overall survival data from the most recently completed arm of the STAMPEDE trial at the annual meeting of the American Society of Clinical Oncology (ASCO). … READ MORE …

Efficacy and safety in the curative treatment of progressive, lymph node-positive prostate cancer

The salvage treatment of men found to have positive lymph nodes after prior (surgical) treatment and the identification of such positive lymph nodes using techniques such as [11C]choline PET/CT scans is still not well established, but it does offer opportunity for some men. … READ MORE …

ADT and radiation for first-line treatment of node-positive (N1) prostate cancer

It’s now a relatively rare occurrence (about 12 percent of new patients) to be newly diagnosed with pelvic lymph node positive (N1) prostate cancer. Traditionally, this had been treated with ADT only because radiation therapy (RT) was thought to be of no benefit in extending survival. … READ MORE …

First-line surgical management of high-risk, localized and locally advanced prostate cancer

For many years surgery was considered to be inappropriate for most men with locally advanced prostate cancer — most particularly those with positive lymph nodes (TxN1Mx) at the time of surgery. … READ MORE …

Overall survival of men diagnosed with advanced disease: an update

On July 8, we wrote about the long-term survival of patients initially diagnosed with metastatic forms of prostate cancer — and a new article on this subject has just appeared in the Journal of Urology. … READ MORE …